vs
Apellis Pharmaceuticals, Inc.（APLS）与SEACOAST BANKING CORP OF FLORIDA（SBCF）财务数据对比。点击上方公司名可切换其他公司
SEACOAST BANKING CORP OF FLORIDA的季度营收约是Apellis Pharmaceuticals, Inc.的1.0倍（$203.3M vs $199.9M），SEACOAST BANKING CORP OF FLORIDA同比增速更快（53.0% vs -5.9%），过去两年SEACOAST BANKING CORP OF FLORIDA的营收复合增速更高（27.2% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
佛罗里达海岸银行公司是总部位于美国佛罗里达州的金融控股企业，提供个人及商业类全品类银行服务，包括存款、个人及企业贷款、财富管理、保险服务等，核心客群为当地个人用户、中小微企业及商业机构。
APLS vs SBCF — 直观对比
营收规模更大
SBCF
是对方的1.0倍
$199.9M
营收增速更快
SBCF
高出58.9%
-5.9%
两年增速更快
SBCF
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $203.3M |
| 净利润 | $-59.0M | — |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 21.4% |
| 净利率 | -29.5% | — |
| 营收同比 | -5.9% | 53.0% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $0.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSSBCF
| Q4 25 | $199.9M | $203.3M | ||
| Q3 25 | $458.6M | $157.3M | ||
| Q2 25 | $178.5M | $151.4M | ||
| Q1 25 | $166.8M | $140.7M | ||
| Q4 24 | $212.5M | $132.9M | ||
| Q3 24 | $196.8M | $130.3M | ||
| Q2 24 | $199.7M | $126.6M | ||
| Q1 24 | $172.3M | $125.6M |
净利润APLSSBCF
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $36.5M | ||
| Q2 25 | $-42.2M | $42.7M | ||
| Q1 25 | $-92.2M | $31.5M | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | $30.7M | ||
| Q2 24 | $-37.7M | $30.2M | ||
| Q1 24 | $-66.4M | $26.0M |
营业利润率APLSSBCF
| Q4 25 | -25.6% | 21.4% | ||
| Q3 25 | 48.7% | 29.8% | ||
| Q2 25 | -18.6% | 36.5% | ||
| Q1 25 | -50.0% | 29.0% | ||
| Q4 24 | -12.3% | 32.8% | ||
| Q3 24 | -24.0% | 30.1% | ||
| Q2 24 | -14.7% | 30.9% | ||
| Q1 24 | -36.0% | 26.9% |
净利率APLSSBCF
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | 23.2% | ||
| Q2 25 | -23.6% | 28.2% | ||
| Q1 25 | -55.3% | 22.4% | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | 23.5% | ||
| Q2 24 | -18.9% | 23.9% | ||
| Q1 24 | -38.5% | 20.7% |
每股收益（稀释后）APLSSBCF
| Q4 25 | $-0.40 | $0.28 | ||
| Q3 25 | $1.67 | $0.42 | ||
| Q2 25 | $-0.33 | $0.50 | ||
| Q1 25 | $-0.74 | $0.37 | ||
| Q4 24 | $-0.30 | $0.39 | ||
| Q3 24 | $-0.46 | $0.36 | ||
| Q2 24 | $-0.30 | $0.36 | ||
| Q1 24 | $-0.54 | $0.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $388.5M |
| 总债务越低越好 | — | $112.8M |
| 股东权益账面价值 | $370.1M | $2.7B |
| 总资产 | $1.1B | $20.8B |
| 负债/权益比越低杠杆越低 | — | 0.04× |
8季度趋势，按日历期对齐
现金及短期投资APLSSBCF
| Q4 25 | $466.2M | $388.5M | ||
| Q3 25 | $479.2M | $306.0M | ||
| Q2 25 | $370.0M | $332.4M | ||
| Q1 25 | $358.4M | $500.6M | ||
| Q4 24 | $411.3M | $476.6M | ||
| Q3 24 | $396.9M | $637.1M | ||
| Q2 24 | $360.1M | $749.5M | ||
| Q1 24 | $325.9M | $682.7M |
总债务APLSSBCF
| Q4 25 | — | $112.8M | ||
| Q3 25 | — | $107.5M | ||
| Q2 25 | — | $107.3M | ||
| Q1 25 | — | $107.1M | ||
| Q4 24 | — | $107.0M | ||
| Q3 24 | — | $106.8M | ||
| Q2 24 | — | $106.6M | ||
| Q1 24 | $93.1M | $106.5M |
股东权益APLSSBCF
| Q4 25 | $370.1M | $2.7B | ||
| Q3 25 | $401.2M | $2.4B | ||
| Q2 25 | $156.3M | $2.3B | ||
| Q1 25 | $164.2M | $2.2B | ||
| Q4 24 | $228.5M | $2.2B | ||
| Q3 24 | $237.1M | $2.2B | ||
| Q2 24 | $264.3M | $2.1B | ||
| Q1 24 | $266.7M | $2.1B |
总资产APLSSBCF
| Q4 25 | $1.1B | $20.8B | ||
| Q3 25 | $1.1B | $16.7B | ||
| Q2 25 | $821.4M | $15.9B | ||
| Q1 25 | $807.3M | $15.7B | ||
| Q4 24 | $885.1M | $15.2B | ||
| Q3 24 | $901.9M | $15.2B | ||
| Q2 24 | $904.5M | $15.0B | ||
| Q1 24 | $831.9M | $14.8B |
负债/权益比APLSSBCF
| Q4 25 | — | 0.04× | ||
| Q3 25 | — | 0.05× | ||
| Q2 25 | — | 0.05× | ||
| Q1 25 | — | 0.05× | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | 0.05× | ||
| Q2 24 | — | 0.05× | ||
| Q1 24 | 0.35× | 0.05× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $188.1M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSSBCF
| Q4 25 | $-14.2M | $188.1M | ||
| Q3 25 | $108.5M | $30.2M | ||
| Q2 25 | $4.4M | $72.3M | ||
| Q1 25 | $-53.4M | $31.0M | ||
| Q4 24 | $19.4M | $179.9M | ||
| Q3 24 | $34.1M | $53.4M | ||
| Q2 24 | $-8.3M | $56.9M | ||
| Q1 24 | $-133.0M | $24.7M |
自由现金流APLSSBCF
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — | ||
| Q1 24 | $-133.3M | — |
自由现金流率APLSSBCF
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — | ||
| Q1 24 | -77.3% | — |
资本支出强度APLSSBCF
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.2% | — |
现金转化率APLSSBCF
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 0.83× | ||
| Q2 25 | — | 1.69× | ||
| Q1 25 | — | 0.99× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.74× | ||
| Q2 24 | — | 1.88× | ||
| Q1 24 | — | 0.95× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
SBCF
暂无分部数据
